




Our Mission is to
Revolutionize Pulmonary
Care and Save Lives by
Curing Lung Disease



Contact Information

Russ Lehrman, PhD
Los Altos, CA 94024
650.969.0206
russ@bio-superior.com

Industry

Biotherapeutics

Development Stage

Preclinical

Year Founded

2017 (major company
pivot in 2019)

Size of Team

4

Grant Funding: \$606K

NSF I-Corps Grant: #1917312
March of Dimes Grants:
#23-FY20-221, #23-FY21-12
NSF SBIR Grant: #2210373

Internal funding: \$152K

Total funding: \$758K

Current Raise

\$2.5M for preclinical
development of BioSurf
leading to IND submission
(mid-to-late 2024).

Patents

PCT/US21/55333 'Surfactant
Treatment Compositions.'

05/05/2022 Provisional filing
on a 2nd technology.

Law Firm

Brubaker Law LLC

Website

www.bio-superior.com

The Problem

Each year in the United States, 60,000 preterm infants are born with Respiratory Distress Syndrome (RDS) due to prematurity. Their lungs are underdeveloped and cannot produce a biomaterial known as lung surfactant, a critical fluid required for breathing. About 20% of infants suffering from RDS develop lung inflammation, known as Bronchopulmonary Dysplasia (BPD), which often results in death or lifelong health issues.

In addition to the human loss, BPD has a significant economic impact on Tier III/IV Hospital Neonatal Intensive Care Unit (NICU) centers. The median cost of care for BPD patients in their first year of life in NICU centers is over \$377,000 and often exceeds \$1,000,000¹. These estimates do not include later hospital re-admissions, home healthcare support or disability accommodations for the survivors.


There is no cure for BPD, despite decades of research.

Animal-derived lung surfactants are currently used to treat preterm infants with RDS. These treatments do not significantly improve the health or survival chances of BPD patients and have important limitations including:

- Raising dedicated herds to harvest lung tissue is environmentally unfriendly and does not scale to meet the increasing scope of the disease.
- The current products require cold storage. This increases cost, limits distribution and therefore access to the medication.
- Animal-derived products pose an ever-present risk of contamination with dangerous pathogens.
- Although it has been clearly demonstrated that mixing lung surfactant with life-saving drugs significantly aids tissue distribution and the potency of respiratory medications, no treatments utilizing animal-derived lung surfactant have been approved.


These and other limitations have motivated a 20-year effort to replace animal-derived lung surfactants with bioengineered versions. Previous efforts have failed. The biggest roadblock has been the inability to make surfactant-specific proteins that are fully active.

BioSuperior stands alone in its ability to manufacture a scalable, stable, and safe bioengineered lung surfactant (BioSurf). We are combining BioSurf with an anti-inflammatory medication for the treatment of BPD.




Data source:

1. Hospitalization costs associated with bronchopulmonary dysplasia in the first year of life. Lapcharoensap et al., J Perinatol 2020 Vol. 40 Issue 1 Pages 130-137



We are developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease



BioSuperior Team

Russ Lehrman
CEO & Founder
Co-founder of SnapDNA
Leadership positions at Nektar, NeXsar, and Pfizer

Lucia Mokres, DVM
VP of Clinical and Regulatory Affairs, CMO EpiBiome
Prin. Clin. Sci. Abbott Vascular

Hong Zhao
Senior Director of Chemistry, Manufacturing and Controls
Dalian Inst., Elan Pharma, American Peptide Company

Ehud Goldin, PhD
VP of Biology, R&D
Weizmann Inst., NGHRI, SENS, Research, Angular Medicine

Advisors

Jeffrey Whitsett, MD
Section Chief, Division of Neonatology, Cincinnati Children's Hospital Professor, University of Cincinnati
Department of Pediatrics

Elizabeth Redente, PhD
Associate Professor, National Jewish Health Division of Cell Biology

James Bridges, PhD
Associate Professor, National Jewish Health Division of Pulmonary & Critical Care

John Patton, PhD
Co-founder of Inhale/Nektar
Founder of Dance Pharma


Our Solution

BioSurf is a novel synthetic pulmonary surfactant. It contains key components that closely match the structure and activity of a human natural surfactant. Due to its synthetic nature, it can be manufactured at scale, making it more accessible to a broader patient population than its animal-derived counterparts. **BioSurf** can be administered using the same protocol as products currently available on the market. No additional training is required. In addition to its core surfactant therapeutic value, a **BioSurf**-based pipeline of products can be developed to deliver potent drugs required to treat severe respiratory disease, such as IPF and adenocarcinoma.

Progress to Date and Milestones

We have overcome limitations in the manufacture of key lung surfactant ingredients. To date, the compounds other companies have made to address these limitations lack full functionality. We plan to file for Orphan Drug Designation (ODD) later this year, and our first IND in 2024.

Our virtual model, partnering with prominent contract labs and academia, allows us to develop our drug candidates efficiently. Once these drug candidates enter early-stage clinical development, we will sublicense them to strategic partners, who will help us complete clinical development and commercialize the products. Beyond **BioSurf**, the company plans to broaden its portfolio to include **gene-delivered therapeutics** that will repair injured tissue, moving from managing to curing lung disease.



Funding

Since the inception of the company, we have garnered over \$750,000 in funding, including grants from the March of Dimes and the National Science Foundation. We are raising an additional \$2,500,000 to reach key preclinical milestones and filing of our first IND.

Prestigious Partnerships

We are proud to be working with prestigious partners, key scientists and clinicians in respiratory medicine.

